stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors the egfr fluorescence in situ hybridization assay分层治疗非小细胞肺癌病人的表皮生长因子受体抑制剂的表皮生长因子受体荧光原位杂交试验.pdf

Diagnostic Pathology BioMed Central Methodology Open Access Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay Marileila Varella-Garcia* Address: University of Colorado Health Sciences Center, Cancer Center, Aurora, CO, USA Email: Marileila Varella-Garcia* - marileila.garcia@ * Corresponding author Published: 15 August 2006 Received: 04 July 2006 Accepted: 15 August 2006 Diagnostic Pathology 2006, 1:19 doi:10.1186/1746-1596-1-19 This article is available from: /content/1/1/19 © 2006 Varella-Garcia; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract DNA fluorescence in situ hybridization (FISH) technology is used to study chromosomal and genomic changes in fixed cell suspensions and tissue block preparations. The technique is based on specific hybridization of small labeled DNA fragments, the probes, to complementary sequences in a target DNA molecule. Demand for FISH assays in formalin-fixed, paraffin-embedded tissues has been increasing, mainly in conditions in which diagnosis is not achieved in cell smears or tissue imprints, such as solid tumors. Moreover, the development of molecular targeted therapies in